On April 30, 2026, the Board of Directors of Godrej Agrovet Limited convened to approve the audited standalone and consolidated financial results for the quarter and fiscal year ending March 31, 2026. The board recommended a final dividend of 110%, totaling ₹11.00 per equity share for the 2025-26 financial year, subject to shareholder approval at the upcoming 35th Annual General Meeting. Additionally, the company approved the allotment of 30,973 equity shares under its 2018 Employees Stock Grant Scheme and noted the granting of 50,507 new stock options.

Godrej Agrovet Limited is a diversified, research-and-development-focused agri-business company with operations spanning animal feed, crop protection, oil palm, dairy, poultry, and processed foods. During 2025, the company expanded its footprint by acquiring a remaining 36.79% stake in Creamline Dairy Products Limited in June 2025 and participating in a rights issue for Astec LifeSciences Limited in July 2025, increasing its shareholding to 67.03%. Other significant corporate developments in 2025 included the acquisition of a 49% stake in Godrej Foods Limited, making it a wholly owned subsidiary as of August 27, 2024, and the realization of ₹33.48 crore from land sales during the 2025-26 fiscal year.

The consolidated revenue for the quarter ended March 31, 2026, reached ₹2,332.65 crore, representing a 9.33% increase compared to ₹2,133.64 crore in the corresponding quarter of the previous year. However, revenue saw a decrease of 14.19% on a quarter-on-quarter (QoQ) basis from ₹2,718.32 crore. Consolidated net profit for the quarter stood at ₹102.28 crore, marking a significant 54.74% year-on-year (YoY) growth from ₹66.10 crore, though it declined 6.79% from the previous quarter’s ₹109.73 crore. Notable financial metrics for the year included an impairment provision of ₹32.96 crore regarding its subsidiary, Godrej Cattle Genetics Private Ltd., and a 110% dividend recommendation for the 2025-26 period.